Vision Loss After Intravitreal Ocriplasmin
نویسندگان
چکیده
منابع مشابه
Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
IMPORTANCE Clinical trials indicate that visual impairment is significantly greater in patients receiving ocriplasmin than placebo. The mechanism of this symptom has not been explained. We report a patient with persistent darkening of her vision after intravitreal ocriplasmin and describe ancillary testing findings that may yield insights into the effects of ocriplasmin and the cause of this sy...
متن کاملTransient visual loss and delayed resolution of vitreomacular traction after intravitreal ocriplasmin
Vitreomacular traction and vitreomacular traction with macular hole are conditions associated with visual disturbance and decreased visual acuity. Recent studies have demonstrated that ocriplasmin is effective and safe in specific patient groups with vitreomacular traction, and hence is recommended as a treatment option. We present here a case report of a patient treated with intravitreal ocrip...
متن کاملMacular Hole Progression following Ocriplasmin Intravitreal Injection
Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VM...
متن کاملRetinal breaks due to intravitreal ocriplasmin
Ocriplasmin represents a new treatment option for numerous vitreoretinopathies involving an abnormal vitreomacular interface. While the drug may circumvent the traditional risks of surgical treatment, pharmacologic vitreolysis is not devoid of risk itself. This report presents two cases, one of vitreomacular traction syndrome and the other of a full-thickness macular hole, both of which were tr...
متن کاملIncomplete Vitreomacular Traction Release Using Intravitreal Ocriplasmin
PURPOSE To report the clinical course of our first 7 consecutive patients treated with intravitreal ocriplasmin (Jetrea(®)). METHODS Retrospective case series of the first 7 patients treated with ocriplasmin between January and December 2013 at an academic tertiary care center. RESULTS The average age was 78.4 years (range: 63-92). Five patients were pseudophakic and 2 patients were phakic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Ophthalmology
سال: 2014
ISSN: 2168-6165
DOI: 10.1001/jamaophthalmol.2013.8258